HDAC6 and Miyoshi myopathy: Furthermore, treatment with HDAC6-selective inhibitor in BTZ-resistant MM cells not only reduced the activation of STAT3 and NF-kB but also decreased the expression of other BTZ-resistant markers, LMP2 and LMP7.